Literature DB >> 11884499

Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.

Guozheng Liu1, Kennedy Mang'era, Ning Liu, Suresh Gupta, Mary Rusckowski, Donald J Hnatowich.   

Abstract

UNLABELLED: Over the past several years, investigators in this laboratory and elsewhere have been studying tumor localization by pretargeting with streptavidin and biotin or with avidin and biotin. Despite encouraging results, difficulties related to endogenous biotin and the immunogenicities of streptavidin and avidin have made a search for alternative strategies sensible. Recently, we have considered the use of DNAs and peptide nucleic acids for this purpose because oligomers can have hybridization affinities equivalent to that of biotin for streptavidin or avidin without the associated difficulties. We now report on the use of a morpholino (MORF), another commercially available synthetic oligomer, for pretargeting applications. MORFs support the nitrogenous bases by nonionic phosphorodiamidate linkages and, besides being nuclease resistant, can display good water solubility.
METHODS: An 18mer MORF and its 18mer complementary MORF (cMORF) were obtained with a primary amine through a 3-member alkyl linker on the 3' equivalent end. An anti--carcinoembryonic antigen IgG antibody (MN14) was conjugated with MORF, whereas cMORF was conjugated with N-hydroxysuccinimide-mercaptoacetyltriglycine (MAG3) to permit radiolabeling with (99m)Tc. The biodistribution of labeled cMORF was first evaluated in normal CD-1 mice. Subsequently, nude mice bearing LS174T tumors received 50 microg conjugated antibody 48 h before the administration of 1.0 microg (7.4 MBq) (99m)Tc-MAG3-cMORF. Control animals received the labeled cMORF without prior administration of the antibody. A clearing step was not used.
RESULTS: Biodistributions in normal mice showed that (99m)Tc-MAG3-cMORF was excreted rapidly through the kidneys, with only 7 percentage injected dose (%ID) remaining within the whole body (excluding urine) at 3 h. In tumor-bearing mice at 24 h, only 11 %ID of the radioactivity remained in the whole body of study animals, and of this amount, 2 %ID/g was in tumor tissue. The sites with the highest %ID were the kidneys, at 4 %ID/g, and the blood, at 0.5 %ID/g; all other organs had <1 %ID/g. At the same time, values for the control animals were 5 %ID (whole body), 0.05 %ID/g (tumor), and 3 %ID (kidneys). All images reflected high uptake in the tumors and low uptake in the normal tissues of the study mice.
CONCLUSION: Pretargeting using MORFs was effective in a mouse tumor model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884499

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  39 in total

1.  Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.

Authors:  Jiang He; Yi Wang; Shuping Dou; Xinrong Liu; Surong Zhang; Guozheng Liu; Donald Hnatowich
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.

Authors:  Guozheng Liu; Shuping Dou; Stephen Baker; Ali Akalin; Dengfeng Cheng; Ling Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

3.  A self-assembling short oligonucleotide duplex suitable for pretargeting.

Authors:  Prabodhika Mallikaratchy; Jeffery Gardner; Lars Ulrik R Nordstrøm; Nicholas J Veomett; Michael R McDevitt; Mark L Heaney; David A Scheinberg
Journal:  Nucleic Acid Ther       Date:  2013-07-13       Impact factor: 5.486

Review 4.  Pretargeted Imaging and Therapy.

Authors:  Mohamed Altai; Rosemery Membreno; Brendon Cook; Vladimir Tolmachev; Brian M Zeglis
Journal:  J Nucl Med       Date:  2017-07-07       Impact factor: 10.057

5.  Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.

Authors:  Guozheng Liu; Shuping Dou; Jiang He; Dongguang Yin; Suresh Gupta; Surong Zhang; Yi Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Appl Radiat Isot       Date:  2006-05-30       Impact factor: 1.513

6.  Detection of Aspergillus fumigatus pulmonary fungal infections in mice with (99m)Tc-labeled MORF oligomers targeting ribosomal RNA.

Authors:  Yuzhen Wang; Ling Chen; Xinrong Liu; Dengfeng Cheng; Guozheng Liu; Yuxia Liu; Shuping Dou; Donald J Hnatowich; Mary Rusckowski
Journal:  Nucl Med Biol       Date:  2012-11-09       Impact factor: 2.408

7.  90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.

Authors:  Guozheng Liu; Shuping Dou; Yuxia Liu; Yuzhen Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2011-11-03       Impact factor: 4.774

8.  Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.

Authors:  Guozheng Liu; Shuping Dou; George Mardirossian; Jiang He; Surong Zhang; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

9.  Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.

Authors:  Shuping Dou; Yuzhen Wang; Bruce Barton; Ling Chen; Mary Rusckowski; Leonard D Shultz; Dale L Greiner; Guozheng Liu
Journal:  Nucl Med Biol       Date:  2013-10-09       Impact factor: 2.408

10.  Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.

Authors:  Brian M Zeglis; Christian Brand; Dalya Abdel-Atti; Kathryn E Carnazza; Brendon E Cook; Sean Carlin; Thomas Reiner; Jason S Lewis
Journal:  Mol Pharm       Date:  2015-08-31       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.